PRO Alert Digest â€” October 13, 2025

Summary of today's articles:
- 67% of patients completed assessments, reducing discontinuation risk by 30%
- 3 FDA-approved ATTR-CM therapies now rely on PRO endpoints to demonstrate patient benefit
- 67% completion rate achieved with proactive reminders, enhancing data quality

ðŸ“Š Cross-Article Insights:
- IMPLEMENTATION PATTERN: 2 articles mention automated reminders as tactical approach

Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications
  https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391
    - **KEY FINDING**: 67% of patients completed assessments, reducing discontinuation risk by 30%.
    - **TACTICAL WIN [ROADMAP]**: Integrate AI-driven reminders to optimize patient engagement and data quality.
    - **MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Growing adoption of PROs in oncology trials as regulatory pressure increases.
    - **CONCERN**: Self-selection bias may skew results toward healthier patients, impacting clinical validity.

Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC
  https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204
    - **KEY FINDING**: 3 FDA-approved ATTR-CM therapies now rely on PRO endpoints to demonstrate patient benefit.
    - **TACTICAL WIN [ROADMAP]**: Integrate AI-driven analytics to predict patient adherence and optimize ePRO workflows.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: New FDA guidance prioritizes PRO integration in cardiovascular trials by Q1 2025.
    - **CONCERN**: Self-selection bias could inflate PRO improvements, requiring rigorous study design safeguards.

Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer
  https://ascopubs.org/doi/10.1200/OA-25-00051
    - **KEY FINDING**: 67% completion rate achieved with proactive reminders, enhancing data quality.
    - **TACTICAL WIN [SHIP NOW]**: Integrate daily push notifications to maintain engagement throughout treatment.
    - **MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Growing emphasis on PROs in regulatory guidelines for cancer trials.
    - **CONCERN**: Self-selection bias may underrepresent severe cases, affecting generalizability.
